Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market to Grow with a CAGR of 7.24% through 2028
Rising lung cancer is expected to drive the Global
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market growth in
the forecast period, 2024-2028.
According to
TechSci Research report, “Epidermal Growth Factor Receptor-Non Small Cell
Lung Cancer Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Epidermal Growth Factor
Receptor-Non Small Cell Lung Cancer Market stood at USD 200.10 Million in 2022
and is anticipated to grow with a CAGR of 7.24% through 2028. The erlotinib
category is to witness a considerable during the forecast period. Erlotinib, a
first-generation EGFR tyrosine kinase inhibitor (TKI), has played a pivotal
role in driving the EGFR-NSCLC market. It inhibits the activity of EGFR,
effectively slowing down cancer cell growth and spread. Despite the emergence
of newer agents, erlotinib remains a key treatment option, particularly for
patients with EGFR-mutated NSCLC who have developed resistance to other
therapies. The drug's well-established efficacy and relatively favorable safety
profile contribute to its continued significance in the market. Online distribution channels enable
patients to research treatment options, understand their condition, and connect
with specialized healthcare professionals, regardless of geographical barriers.
This virtual connectivity empowers patients and caregivers to make informed
decisions and seek appropriate therapies, contributing to the expansion of the
EGFR-NSCLC market.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market”
The Global Epidermal
Growth Factor Receptor-Non Small Cell Lung Cancer Market is segmented into Type,
Distribution Channel and company.
Based on the
Drug Type, the Erlotinib segment is anticipated to witness substantial market
growth throughout the forecast period. Erlotinib, a tyrosine kinase inhibitor,
is anticipated to be a key driver in propelling the growth of the Global
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)
market. As a targeted therapy, erlotinib specifically inhibits the epidermal
growth factor receptor (EGFR), a protein often overexpressed in NSCLC. The drug
has demonstrated efficacy in improving progression-free survival and overall
survival rates in EGFR-NSCLC patients, establishing itself as a frontline
treatment option. The increasing adoption of erlotinib is influenced by its
ability to offer patients a more tolerable and effective alternative to
traditional chemotherapy. Its targeted mechanism minimizes damage to healthy
cells, leading to fewer side effects and an enhanced quality of life for
patients. Moreover, ongoing research and clinical trials exploring combination
therapies involving erlotinib further contribute to its market prominence.
Pharmaceutical companies investing in the production and distribution of
erlotinib are well-positioned to capitalize on the expanding EGFR-NSCLC market.
Based on the
Distribution Channel segment, the Online distribution channels segment has been
the dominant force in the market. The growth of the Global Epidermal Growth
Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market is poised for
acceleration with the increasing prominence of online distribution channels.
The digital transformation of healthcare, coupled with the global shift towards
telemedicine and online platforms, is reshaping the accessibility and
distribution of EGFR-NSCLC treatments. Online channels offer a streamlined and
efficient means for pharmaceutical companies to reach a wider audience of
healthcare providers and patients, facilitating the rapid dissemination of
information, product availability, and seamless transactions. These online
platforms empower healthcare professionals to access the latest research
findings, treatment guidelines, and pharmaceutical innovations related to
EGFR-NSCLC. Patients, in turn, benefit from improved access to information,
teleconsultations, and convenient avenues for obtaining prescribed medications.
The digitization of distribution also enhances supply chain efficiency,
reducing lead times and ensuring a consistent and reliable availability of
EGFR-NSCLC drugs. As the healthcare landscape continues to embrace online
platforms, pharmaceutical companies leveraging digital distribution channels
stand to gain a competitive edge, expanding their market reach and optimizing
the overall patient experience.
Major companies
operating in Global Epidermal Growth Factor Receptor-Non Small Cell Lung
Cancer Market are:
- F. Hoffmann-La Roche Ltd.
- Boehringer Ingelheim International GmbH
- AstraZeneca plc.
- Pfizer Inc.
- Novartis AG
- Johnson & Johnson Services, Inc.
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- Genentech, Inc.
- Astellas Pharma Inc.
Download Free Sample Report
Customers can
also request 10% free customization on this report
“The Global Epidermal
Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market is
propelled by several key drivers. Firstly, advancements in targeted therapies,
particularly EGFR inhibitors, have significantly improved treatment outcomes.
Additionally, rising incidence of NSCLC, coupled with increasing awareness and
early diagnosis, fuels market growth. The demand for personalized medicine and
the advent of companion diagnostics contribute to the expansion of EGFR-NSCLC
treatment options. Furthermore, ongoing research and development efforts,
supported by collaborations between pharmaceutical companies and academic
institutions, drive innovation in this market. The introduction of novel drugs,
along with regulatory approvals, further stimulates market dynamics. Overall,
these factors collectively underscore the robust growth of the Global
EGFR-NSCLC market.” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“Epidermal
Growth Factor Receptor-Non Small Cell Lung Cancer Market - Global Industry
Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug
Type (Erlotinib, Afatinib, Gefitinib, Osimertinib, Dacomitinib), By
Distribution Channel (Online, Offline), By Region, By Competition”,
has evaluated the future growth potential of Global Epidermal Growth Factor
Receptor-Non Small Cell Lung Cancer Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Epidermal Growth Factor Receptor-Non Small Cell Lung
Cancer Market.
Contact
TechSci Research
LLC
420 Lexington
Avenue, Suite 300,
New York, United
States- 10170
Tel:
+1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com